Loading...
The search for nonstimulant medications for attention-deficit/hyperactivity disorder (ADHD) continues. In a manufacturer-sponsored, two-phase study, investigators performed the first long-term efficacy study of guanfacine extended-release (GXR), an alpha-2-adrenergic agonist, at 67 sites in the U.S., Europe, and Canada.
First, 526 school-age participants with ADHD (mean age, 11; 84% with combined subtype) received open-label GXR; in the first 7 weeks, doses were optimized. By week 13, a total of 316 participants (60%) responded on the combined primary outcome, an ADHD measure (69%) and a global-functioning measure (76%). The responders continued in a double-blind, placebo-controlled, 26-week study; patients randomized to placebo underwent bl…